Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Cara Therapeutics (CARA)
Cara Therapeutics (CARA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 183,512
  • Shares Outstanding, K 53,974
  • Annual Sales, $ 41,870 K
  • Annual Income, $ -85,470 K
  • 60-Month Beta 0.88
  • Price/Sales 4.23
  • Price/Cash Flow N/A
  • Price/Book 1.30
Trade CARA with:

Options Overview Details

View History
  • Implied Volatility 29.73% ( -30.84%)
  • Historical Volatility 56.28%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 131.01% on 10/21/22
  • IV Low 29.73% on 05/26/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 34
  • Volume Avg (30-Day) 108
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 7,618
  • Open Int (30-Day) 8,634

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -0.53
  • Number of Estimates 5
  • High Estimate -0.44
  • Low Estimate -0.60
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -562.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.24 +4.94%
on 05/26/23
4.67 -27.19%
on 05/16/23
-0.60 (-15.00%)
since 04/26/23
3-Month
3.24 +4.94%
on 05/26/23
10.39 -67.28%
on 03/03/23
-6.63 (-66.10%)
since 02/24/23
52-Week
3.24 +4.94%
on 05/26/23
12.98 -73.81%
on 08/11/22
-4.61 (-57.55%)
since 05/26/22

Most Recent Stories

More News
Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

/PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England's National Institute...

CARA : 3.40 (+3.66%)
Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

/CNW/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England's National Institute for...

CARA : 3.40 (+3.66%)
Cara: Q1 Earnings Snapshot

Cara: Q1 Earnings Snapshot

CARA : 3.40 (+3.66%)
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 10% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

DARE : 0.9803 (-0.29%)
CARA : 3.40 (+3.66%)
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates

scPharmaceuticals, Inc. (SCPH) delivered earnings and revenue surprises of 16.67% and 20.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

SCPH : 10.57 (+2.92%)
CARA : 3.40 (+3.66%)
Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of -0.66% and 37.92%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

RGNX : 18.20 (-0.33%)
CARA : 3.40 (+3.66%)
Stocks Slide After the Fed Chairman Powell Warns Rates Will Likely Be Higher

Morning Markets The S&P 500 Index ( $SPX ) ( SPY ) today is down -0.41%, the Dow Jones Industrials Index ( $DOWI ) ( DIA ) is down -0.46%, and the Nasdaq 100 Index ( $IUXX ) ( QQQ ) is down -0.25%. Stock...

ESM23 : 4,225.50 (+0.29%)
NQM23 : 14,400.50 (+0.47%)
META : 262.04 (+3.70%)
DKS : 125.41 (+2.49%)
UAL : 47.26 (-0.46%)
TCOM : 31.49 (+0.90%)
SQSP : 29.12 (-0.44%)
DISH : 6.66 (-0.15%)
NTNX : 29.47 (-0.71%)
RIVN : 15.14 (+3.91%)
KEY : 9.89 (-2.18%)
ZYXI : 9.40 (+0.21%)
S&P Futures Tick Higher Ahead of Powell Testimony

March S&P 500 futures (ESH23) are trending up +0.21% this morning after three major U.S. benchmark indices ended the regular session mixed as market participants braced for Federal Reserve Chairman Jerome...

ESH23 : 3,957.05s (-0.09%)
AAPL : 175.43 (+1.41%)
MRK : 111.07 (-1.10%)
TSLA : 193.17 (+4.72%)
BNR.D.DX : 74.700 (+1.11%)
RIVN : 15.14 (+3.91%)
CARA : 3.40 (+3.66%)
DXC : 24.75 (+2.23%)
ANET : 170.35 (+9.06%)
KRP : 15.28 (+0.53%)
These 2 Stocks Are Plunging After Hours Monday

The market closed mixed, but these two companies gave investors some bad news.

COMP : 3.43 (-4.19%)
$DOWI : 33,093.34 (+1.00%)
$SPX : 4,205.45 (+1.30%)
$NASX : 12,975.69 (+2.19%)
CVGW : 33.09 (+0.79%)
CARA : 3.40 (+3.66%)
Cara Therapeutics (CARA) Reports Q4 Loss, Misses Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of -69.70% and 76.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CARA : 3.40 (+3.66%)
VRDN : 23.73 (-0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States.

See More

Key Turning Points

3rd Resistance Point 3.65
2nd Resistance Point 3.53
1st Resistance Point 3.47
Last Price 3.40
1st Support Level 3.29
2nd Support Level 3.17
3rd Support Level 3.11

See More

52-Week High 12.98
Fibonacci 61.8% 9.26
Fibonacci 50% 8.11
Fibonacci 38.2% 6.96
Last Price 3.40
52-Week Low 3.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar